StockWatch
·
HomeLiveReports
Biotechnology: Pharmaceutical Preparations
Quarterly ResultMar 29, 2026, 08:57 PM

Novartis AG Reports Q4 2025 Financial Results

AI Summary

Novartis AG filed a 6-K report including its Q4 2025 financial report and condensed financial report. This provides investors with an update on the company's financial performance, which is crucial for assessing its valuation and future prospects.

Key Highlights

  • Includes Q4 2025 financial report.
  • Includes condensed financial report.
  • Provides update on company's financial performance.
View SEC Filing
NVS
Biotechnology: Pharmaceutical Preparations
NOVARTIS AG

Price Impact

More from NVS

Clinical Trial1d ago, 5:27 PM

Novartis Pelacarsen Trial Fails Primary Endpoint for Cardiovascular Events

Quarterly ResultJul 21, 6:31 AM

Novartis Q2 Sales +1% (cc); Reaffirms FY26 Guidance

Clinical TrialJun 11, 8:02 AM

Novartis del-brax Phase I/II FSHD study meets primary biomarker endpoint

More in Quarterly Result

VSCO1d ago, 7:26 AM

Victoria's Secret Q2 Sales Up 10.4% to $1.61B; Net Income Soars to $183M

ASAN2d ago, 4:30 PM

Asana Q2 Revenue $216.4M; Net Loss Narrows to $39.2M

NX2d ago, 4:29 PM

Quanex Building Products Q3 Sales Rise 1.3% to $501.8M; Debt Repaid